Nanoparticles for drug delivery in cancer treatment

Barbara Haley, Eugene Frenkel

Research output: Contribution to journalArticle

497 Citations (Scopus)

Abstract

Nanoparticles (size in nanometer range) provide a new mode of cancer drug delivery functioning as a carrier for entry through fenestrations in tumor vasculature allowing direct cell access. These particles allow exquisite modification for binding to cancer cell membranes, the microenvironment, or to cytoplasmic or nuclear receptor sites. This results in delivery of high drug concentrations to the targeted cancer cell, with reduced toxicity of normal tissue. Several such engineered drugs are in clinical practice, including liposomal doxorubicin and albumin conjugate paclitaxel. The carrier mediated paclitaxel has already shown significant efficacy in taxane resistant cancers, an approach highly relevant in prostate cancer, where taxanes are the treatment of choice. Other modifications including transferrin receptor and folate receptor targeted drug delivery molecules are in study. This new technology provides many exciting therapeutic approaches for targeted high concentration drug delivery to cancer cells with reduced injury of normal cells.

Original languageEnglish (US)
Pages (from-to)57-64
Number of pages8
JournalUrologic Oncology: Seminars and Original Investigations
Volume26
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Nanoparticles
Pharmaceutical Preparations
Neoplasms
Paclitaxel
Drug Receptors
Cellular Microenvironment
Taxoids
Transferrin Receptors
Cytoplasmic and Nuclear Receptors
Folic Acid
Albumins
Prostatic Neoplasms
Cell Membrane
Technology
Wounds and Injuries

Keywords

  • Drug delivery
  • Nanoparticles
  • Urologic cancer

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Nanoparticles for drug delivery in cancer treatment. / Haley, Barbara; Frenkel, Eugene.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 26, No. 1, 01.2008, p. 57-64.

Research output: Contribution to journalArticle

@article{3b868f3fc9a143099eca6b02d7ca06c0,
title = "Nanoparticles for drug delivery in cancer treatment",
abstract = "Nanoparticles (size in nanometer range) provide a new mode of cancer drug delivery functioning as a carrier for entry through fenestrations in tumor vasculature allowing direct cell access. These particles allow exquisite modification for binding to cancer cell membranes, the microenvironment, or to cytoplasmic or nuclear receptor sites. This results in delivery of high drug concentrations to the targeted cancer cell, with reduced toxicity of normal tissue. Several such engineered drugs are in clinical practice, including liposomal doxorubicin and albumin conjugate paclitaxel. The carrier mediated paclitaxel has already shown significant efficacy in taxane resistant cancers, an approach highly relevant in prostate cancer, where taxanes are the treatment of choice. Other modifications including transferrin receptor and folate receptor targeted drug delivery molecules are in study. This new technology provides many exciting therapeutic approaches for targeted high concentration drug delivery to cancer cells with reduced injury of normal cells.",
keywords = "Drug delivery, Nanoparticles, Urologic cancer",
author = "Barbara Haley and Eugene Frenkel",
year = "2008",
month = "1",
doi = "10.1016/j.urolonc.2007.03.015",
language = "English (US)",
volume = "26",
pages = "57--64",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Nanoparticles for drug delivery in cancer treatment

AU - Haley, Barbara

AU - Frenkel, Eugene

PY - 2008/1

Y1 - 2008/1

N2 - Nanoparticles (size in nanometer range) provide a new mode of cancer drug delivery functioning as a carrier for entry through fenestrations in tumor vasculature allowing direct cell access. These particles allow exquisite modification for binding to cancer cell membranes, the microenvironment, or to cytoplasmic or nuclear receptor sites. This results in delivery of high drug concentrations to the targeted cancer cell, with reduced toxicity of normal tissue. Several such engineered drugs are in clinical practice, including liposomal doxorubicin and albumin conjugate paclitaxel. The carrier mediated paclitaxel has already shown significant efficacy in taxane resistant cancers, an approach highly relevant in prostate cancer, where taxanes are the treatment of choice. Other modifications including transferrin receptor and folate receptor targeted drug delivery molecules are in study. This new technology provides many exciting therapeutic approaches for targeted high concentration drug delivery to cancer cells with reduced injury of normal cells.

AB - Nanoparticles (size in nanometer range) provide a new mode of cancer drug delivery functioning as a carrier for entry through fenestrations in tumor vasculature allowing direct cell access. These particles allow exquisite modification for binding to cancer cell membranes, the microenvironment, or to cytoplasmic or nuclear receptor sites. This results in delivery of high drug concentrations to the targeted cancer cell, with reduced toxicity of normal tissue. Several such engineered drugs are in clinical practice, including liposomal doxorubicin and albumin conjugate paclitaxel. The carrier mediated paclitaxel has already shown significant efficacy in taxane resistant cancers, an approach highly relevant in prostate cancer, where taxanes are the treatment of choice. Other modifications including transferrin receptor and folate receptor targeted drug delivery molecules are in study. This new technology provides many exciting therapeutic approaches for targeted high concentration drug delivery to cancer cells with reduced injury of normal cells.

KW - Drug delivery

KW - Nanoparticles

KW - Urologic cancer

UR - http://www.scopus.com/inward/record.url?scp=37649010361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37649010361&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2007.03.015

DO - 10.1016/j.urolonc.2007.03.015

M3 - Article

C2 - 18190833

AN - SCOPUS:37649010361

VL - 26

SP - 57

EP - 64

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 1

ER -